Skip to main content

Table 3 Dosimetry comparison of [18F]-JK-PSMA-7 with other 18F-labled PSMA tracers

From: Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

Organ[18F]-JK-PSMA-7
This work
[18F]-PSMA-1007
Giesel et al. [10]
[18F]-DCFPyL
Szabo et al. [7]
[18F]-DCFBC
Cho et al. [6]
Mean absorbed dose [mGy/MBq]
 Number of patients10345
 Used dosimetry softwareQDOSE,
ABX-CRO, Germany
QDOSE,
ABX-CRO, Germany
MIM Software,
Cleveland, Ohio
ANALYZE,
BIR, Mayo Clinic
 Kidneys1.76E−01
(6.52E−02 SD)
1.70E−01
(3.09E−02 SD)
9.45E−02
(n.a.)
2.84E−02
(3.81-03 SD)
 Lungs1.10E−02
(2.16E−03 SD)
1.11E−02
(2.60E−04 SD)
1.08E−02
(n.a.)
2.45E−02
(2.99-03 SD)
 Liver7.61E−02
(1.83E−02 SD)
6.02E−02
(6.24E−04 SD)
3.80E−02
(n.a.)
2.46E−02
(4.16-03 SD)
 Spleen1.89E−02
(8.28E−03 SD)
7.39E−02
(2.96E−02 SD)
1.85E−02
(n.a.)
1.72E−02
(1.05E−03 SD)
 Salivary glands4.68E−02
(1.50E−02 SD)
9.00E−02
(n.a.)
2.68E−02
(n.a.)
n.a.
 Effective dose1.09E−02
(2.37E−03 SD)
2.20E−02
(2.08E−04 SD)
1.39E−02
(n.a.)
1.99E−02
(1.34E−03 SD)
Mean residence time [MBq·h/MBq]
 Kidneys2.26E−01
(7.83E−02 SD)
2.64E−01
(5.03E−03 SD)
2.17E−01
(n.a.)
3.50E−02
(5.84E−03 SD)
 Lungs4.39E−02
(7.16E−03 SD)
n.a.3.70E−02
(n.a.)
1.09E–01
(1.87E−02 SD)
 Liver5.70E−01
(1.31E −01 SD)
4.42E−01
(2.87E−02 SD)
2.60E−01
(n.a.)
1.59E−01
(3.29E−02 SD)
 Spleen2.32E−02
(7.09E−03)
6.29E−02
(2.89E−02 SD)
2.07E−02
(n.a.)
1.01E−02
(8.92E−04 SD)
 Salivary glands1.75E−02
(2.68E−03 SD)
1.37E−02
(3.64E−03 SD)
6.95E−03
(n.a.)
n.a.
 Whole-body1.93E+00
(1.48E−01 SD)
2.64E+00
(0.00 SD)*
1.96E+00
(n.a.)
2.37E+00
(9.09E−02 SD)
  1. n.a. not available, SD standard deviation
  2. *The residence time for the whole-body was the same for all three patients [10]